Athens Research/Cambio - Excellence in Molecular Biology/10 AEU (100ug)/ATW0090-100

价格
面议
货号:ATW0090-100
浏览量:57
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Aptamers

Aptamers: Catalogue Aptamers

Please remember to pick your Modification from "Related items"

If the listed modifications do not meet your needs many other modifications are available on request

All Aptamers from Base Pair Bio are available with the following modifications

Please choose your modification and add as an extra catalogue number:

ATWUNMOD - Unmodified

ATWAMINE - Amine modification

ATWBIOTIN - Biotin modification

ATWTHIOL - Thiol modification (extra charge)

ATWFLUOR - Fluor (all) modification (extra charge)

  • Catalogue
  • Description
  • Notes

ERK2 (aa171-189) Phospho aa183

pERK2 peptide Thr183 (aa 171-189) Aptamer ATW0090

Base Pair Bio

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
ATW0090-100ERK2 (aa171-189) Phospho aa18310 AEU (100ug)POAQuantityAdd to Order
ATW0090-25ERK2 (aa171-189) Phospho aa1832.5 AEU (25ug)POAQuantityAdd to Order

ERK2 (aa171-189) Phospho aa183

pERK2 peptide Thr183 (aa 171-189) Aptamer ATW0090

Base Pair Bio

ERK2 (Mitogen-activated protein kinase 1, also known as MAPK1, p42MAPK, and ERK2)is a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases.

This aptamer was selected by scientists at Base Pair Biotechnologies using proprietary methods and phosphorylated 183 ERK2 (aa 171-189) peptide CVADPDHDHTGFL(t)EYVATR as a target

Target: ERK2 (aa171-189) Phospho aa183

Target Species: multi-species

Target Type: peptide

Dissociation Constant (Kd): 7.7 nM

Default 3" Linker (Spacer) is 10T. Please submit a custom quote request for other options.

*Please note that aptamers have much lower molecular weights than antibodies. Thus, there are typically five to fifteen times as many moles or molecules of aptamers present in a solution containing an equal mass. For example, 100 micrograms of an aptamer is equivalent to 0.5 to 1.5 mg of antibody, depending on the particular aptamer.

ATW0090 - Phosphorylated 183 ERK2 (aa 171?ÛÒ189)

Image courtesy of Ctr for Study of Systems Biology at Georgia Tech

Datasheet

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

ERK2 (aa171-189) Phospho aa183

pERK2 peptide Thr183 (aa 171-189) Aptamer ATW0090

Base Pair Bio

Please note that aptamers have much lower molecular weights than antibodies. Thus, there are typically five to fifteen times as many moles or molecules of aptamers present in a solution containing an equal mass. For example, 100 micrograms of an aptamer is equivalent to 0.5 to 1.5 mg of antibody, depending on the particular aptamer.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.